High Levels of Aromatic Amino Acids in Gastric Juice during the Early Stages of Gastric Cancer Progression

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Deng, Kai ^a   Lin, Sanren ^a   Zhou, Liya ^a   Li, Yuan ^a   Chen, Mo ^a   Wang, Yingchun ^a   Li, Yuwen ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC AMINO ACID; PHENYLALANINE; TRYPTOPHAN; TYROSINE;

ADULT; AMINO ACID ANALYSIS; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER STAGING; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; EARLY DIAGNOSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; QUANTITATIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; STOMACH JUICE;

AMINO ACIDS, AROMATIC; BIOLOGICAL ASSAY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE PROGRESSION; FEMALE; FLUORESCENCE; GASTRIC JUICE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; REPRODUCIBILITY OF RESULTS; STOMACH NEOPLASMS;

EID: 84869076586     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049434     Document Type: Article

References (44)

1. Arvanitakis C, Nikopoulos A, Giannoulis E, Theoharidis A, Georgilas V, et al. (1992) The impact of early or late diagnosis on patient survival in gastric cancer in Greece. Hepatogastroenterology 39: 355-357.
2. Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ, (2009) Gastric cancer. Lancet 374: 477-490.
3. Cunningham SC, Kamangar F, Kim MP, Hammoud S, Haque R, et al. (2005) Survival after gastric adenocarcinoma resection: eighteen-year experience at a single institution. J Gastrointest Surg 9: 718-725.
4. Itoh H, Oohata Y, Nakamura K, Nagata T, Mibu R, et al. (1989) Complete ten-year postgastrectomy follow-up of early gastric cancer. Am J Surg 158: 14-16.
5. Pathirana A, Poston GJ, (2001) Lessons from Japan-endoscopic management of early gastric and oesophageal cancer. Eur J Surg Oncol 27: 9-16.
6. Yalamarthi S, Witherspoon P, McCole D, Auld CD, (2004) Missed diagnoses in patients with upper gastrointestinal cancers. Endoscopy 36: 874-879.
7. Amin A, Gilmour H, Graham L, Paterson-Brown S, Terrace J, et al. (2002) Gastric adenocarcinoma missed at endoscopy. J R Coll Surg Edinb 47: 681-684.
8. Duraker N, Naci CA, Gencler N, (2002) The prognostic significance of gastric juice CA 19-9 and CEA levels in gastric carcinoma patients. Eur J Surg Oncol 28: 844-849.
9. Miki K, Morita M, Sasajima M, Hoshina R, Kanda E, et al. (2003) Usefulness of gastric cancer screening using the serum pepsinogen test method. Am J Gastroenterol 98: 735-739.
10. Miki K, (2006) Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer 9: 245-253.
11. McDermott EW, Barron ET, Smyth PP, O'Higgins NJ, (1990) Premorphological metabolic changes in human breast carcinogenesis. Br J Surg 77: 1179-1182.
12. Zhou LY, Lin SR, Li Y, Geng QM, Ding SG, et al. (2011) The intrinsic fluorescence spectrum of dilute gastric juice as a novel diagnostic tool for gastric cancer. J Dig Dis 12: 279-285.
13. Sun XN, Zhou LY, Lin SR, Zhao YM, Lv JQ (2004) Study on autofluorescence spectrum of gastric juice in clinical screening for gastric cancer. Chin J Dig: 10-13 (in Chinese).
14. Li Y, Lin SR, Zhou LY, Peng JR, Guo HL (2003) Preliminary identification of a specific fluorescent substance in gastric juice from patients with gastric carcinoma. Chin J Dig: 11-14 (in Chinese).
15. Deng K, Lin S, Zhou L, Geng Q, Li Y, et al. (2011) Three aromatic amino acids in gastric juice as potential biomarkers for gastric malignancies. Anal Chim Acta 694: 100-107.
16. Lansdown M, Quirke P, Dixon MF, Axon AT, Johnston D, (1990) High grade dysplasia of the gastric mucosa: a marker for gastric carcinoma. Gut 31: 977-983.
17. Deng K, Lin S, Zhou L, Geng Q, Li Y, et al. (2011) Three aromatic amino acids in gastric juice as potential biomarkers for gastric malignancies. Anal Chim Acta 694: 100-107.
18. Lian W, Ma DJ, Xu X, Chen Y, Wu YL, (2012) Rapid high-performance liquid chromatography method for determination of tryptophan in gastric juice. J Dig Dis 13: 100-106.
19. Shein-Chung Chowm, Wang H, Shao J (2008) Sample Size Calculations in Clinical Research, 2nd edition. Boca Raton, Florida: Chapman &Hall/CRC.
20. Fan C, Zhang D, Zhang CH, (2011) On sample size of the kruskal-wallis test with application to a mouse peritoneal cavity study. Biometrics 67: 213-224.
21. Lachenbruch PA, Clements PJ, (1991) Anova, kruskal-wallis, normal scores and unequal variance. Communications in Statistics- Theory and MethodsCommunications in Statistics- Theory and MethodsCommunications in Statistics- Theory and Methods 20: 107-126.
22. Muscaritoli M, Conversano L, Petti MC, Torelli GF, Cascino A, et al. (1999) Plasma amino acid concentrations in patients with acute myelogenous leukemia. Nutrition 15: 195-199.
23. Cascino A, Muscaritoli M, Cangiano C, Conversano L, Laviano A, et al. (1995) Plasma amino acid imbalance in patients with lung and breast cancer. Anticancer Res 15: 507-510.
24. Laviano A, Cascino A, Muscaritoli M, Fanfarillo F, Rossi FF, (2003) Tumor-induced changes in host metabolism: a possible role for free tryptophan as a marker of neoplastic disease. Adv Exp Med Biol 527: 363-366.
25. Huang Z, McWilliams A, Lui H, McLean DI, Lam S, et al. (2003) Near-infrared Raman spectroscopy for optical diagnosis of lung cancer. Int J Cancer 107: 1047-1052.
26. Draga RO, Grimbergen MC, Vijverberg PL, van SCF, Jonges TG, et al. (2010) In vivo bladder cancer diagnosis by high-volume Raman spectroscopy. Anal Chem 82: 5993-5999.
27. Ganapathy V, Thangaraju M, Prasad PD, (2009) Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther 121: 29-40.
28. Fuchs BC, Bode BP, (2005) Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime. Semin Cancer Biol 15: 254-266.
29. Nawashiro H, Otani N, Shinomiya N, Fukui S, Ooigawa H, et al. (2006) L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer 119: 484-492.
30. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, et al. (2008) Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. Br J Cancer 98: 742-748.
31. Yoon JH, Kim YB, Kim MS, Park JC, Kook JK, et al. (2004) Expression and functional characterization of the system L amino acid transporter in KB human oral epidermoid carcinoma cells. Cancer Lett 205: 215-226.
32. Kobayashi H, Ishii Y, Takayama T, (2005) Expression of L-type amino acid transporter 1 (LAT1) in esophageal carcinoma. J Surg Oncol 90: 233-238.
33. Nakanishi K, Ogata S, Matsuo H, Kanai Y, Endou H, et al. (2007) Expression of LAT1 predicts risk of progression of transitional cell carcinoma of the upper urinary tract. Virchows Arch 451: 681-690.
34. Kobayashi K, Ohnishi A, Promsuk J, Shimizu S, Kanai Y, et al. (2008) Enhanced tumor growth elicited by L-type amino acid transporter 1 in human malignant glioma cells. Neurosurgery 62: 493-503; discussion 503-504.
35. Sakata T, Ferdous G, Tsuruta T, Satoh T, Baba S, et al. (2009) L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer. Pathol Int 59: 7-18.
36. Talvensaari A, Apaja-Sarkkinen M, Hoyhtya M, Westerlund A, Puistola U, et al. (1999) Matrix metalloproteinase 2 immunoreactive protein appears early in cervical epithelial dedifferentiation. Gynecol Oncol 72: 306-311.
37. Rudolph-Owen LA, Chan R, Muller WJ, Matrisian LM, (1998) The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis. Cancer Res 58: 5500-5506.
38. Cai M, Onoda K, Takao M, Kyoko IY, Shimpo H, et al. (2002) Degradation of tenascin-C and activity of matrix metalloproteinase-2 are associated with tumor recurrence in early stage non-small cell lung cancer. Clin Cancer Res 8: 1152-1156.
39. Sier CF, Casetta G, Verheijen JH, Tizzani A, Agape V, et al. (2000) Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers. Clin Cancer Res 6: 2333-2340.
40. Nosho K, Yamamoto H, Taniguchi H, Adachi Y, Yoshida Y, et al. (2004) Interplay of insulin-like growth factor-II, insulin-like growth factor-I, insulin-like growth factor-I receptor, COX-2, and matrix metalloproteinase-7, play key roles in the early stage of colorectal carcinogenesis. Clin Cancer Res 10: 7950-7957.
41. Axon A, (2006) Symptoms and diagnosis of gastric cancer at early curable stage. Best Pract Res Clin Gastroenterol 20: 697-708.
42. Wang RT, Zao JS, Liu D, Peng BS, He PY, (1991) The gastric cancer series tests with minimum volume of gastric juice collected by advanced micro device. J Beijing Med Univ 23: 9-11 (in Chinese).
43. Muretto P, Ruzzo A, Pizzagalli F, Graziano F, Maltese P, et al. (2008) Endogastric capsule for E-cadherin gene (CDH1) promoter hypermethylation assessment in DNA from gastric juice of diffuse gastric cancer patients. Ann Oncol 19: 516-519.
44. Muretto P, Graziano F, Staccioli MP, Barbanti I, Bartolucci A, et al. (2003) An endogastric capsule for measuring tumor markers in gastric juice: an evaluation of the safety and efficacy of a new diagnostic tool. Ann Oncol 14: 105-109.